Collaborations

Insert Therapeutics signs agreement for anticancer compound Tubulysin

Published in Health Business Week, February 16th, 2007

Arrowhead Research Corp. (ARWR) announced that its majority-owned subsidiary, Insert Therapeutics, Inc., has entered into a collaboration agreement with R&D-Biopharmaceuticals GmbH to develop and commercialize conjugates of the potent anti-cancer compound tubulysin with Insert's proprietary drug delivery system, Cyclosert.

The agreement provides a research license and an option for an exclusive license to develop and commercialize tubulysin-polymer conjugates.

"With this agreement, Insert has secured proprietary rights to one of the most potent anti-cancer compounds known," said Edward L. Jacobs, Insert's CEO and president. "The major challenge to...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2007-02-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry